Robeco Institutional Asset Management B.V. Decreases Stake in Becton, Dickinson and Company $BDX

Key Points

• Robeco Institutional Asset Management B.V. decreased its stake in Becton, Dickinson and Company by 25.9%, selling 10,496 shares, leaving them with 30,103 shares valued at approximately $5.18 million.
• Several hedge funds, including GQG Partners and Vanguard Group, made significant investments or increased their stakes in Becton, Dickinson and Company, demonstrating strong institutional interest in the company.
• Following a recent earnings report where Becton, Dickinson exceeded analysts' expectations with $3.68 EPS, analysts have given the stock a consensus rating of "Hold" with an average target price of $205.40.

Robeco Institutional Asset Management B.V. reduced its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 25.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,103 shares of the medical instruments supplier's stock after selling 10,496 shares during the period. Robeco Institutional Asset Management B.V.'s holdings in Becton, Dickinson and Company were worth $5,185,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the company. GQG Partners LLC bought a new stake in Becton, Dickinson and Company during the first quarter worth approximately $689,833,000. Vanguard Group Inc. increased its stake in Becton, Dickinson and Company by 4.7% during the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier's stock worth $6,414,322,000 after acquiring an additional 1,259,750 shares during the last quarter. Nuveen LLC bought a new stake in Becton, Dickinson and Company during the first quarter worth approximately $211,097,000. Kingstone Capital Partners Texas LLC bought a new stake in Becton, Dickinson and Company during the second quarter worth approximately $155,080,000. Finally, Massachusetts Financial Services Co. MA increased its stake in Becton, Dickinson and Company by 10.8% during the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier's stock worth $1,567,654,000 after acquiring an additional 667,957 shares during the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Trading Down 0.9%

BDX opened at $191.94 on Tuesday. The stock has a market cap of $55.02 billion, a price-to-earnings ratio of 34.52, a P/E/G ratio of 1.51 and a beta of 0.25. The stock's 50 day moving average price is $189.21 and its 200-day moving average price is $186.79. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. The firm had revenue of $5.51 billion during the quarter, compared to analyst estimates of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.Becton, Dickinson and Company's quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, equities analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Monday, September 8th were issued a $1.04 dividend. The ex-dividend date was Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company's payout ratio is presently 74.82%.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on BDX. Wells Fargo & Company boosted their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research note on Friday, August 8th. Morgan Stanley boosted their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Piper Sandler reissued a "neutral" rating and set a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Wall Street Zen raised Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Finally, Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Becton, Dickinson and Company in a research note on Saturday, September 27th. Three analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $205.40.

Insider Buying and Selling

In related news, EVP Michael David Garrison sold 1,185 shares of the business's stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares in the company, valued at approximately $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Claire Fraser sold 917 shares of the business's stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director owned 22,226 shares of the company's stock, valued at $4,167,375. The trade was a 3.96% decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,023 shares of company stock valued at $562,036 in the last quarter. 0.36% of the stock is owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.